Revenue and Income - For the year ended December 31, 2024, the company recognized 81,855inlicensingandroyaltyrevenueand13,750 in revenue for device processing work, compared to 40,502inlicensingandroyaltyrevenuefortheyearendedDecember31,2023,indicatingasignificantincreaseinrevenue[220].−Otherincomeincreasedby196554,102 in 2024, compared to 187,233in2023,mainlyduetoincreasedinterestincomeandadecreaseincommitmentfees[226].OperatingExpenses−Thecompany′stotaloperatingexpensesfortheyearendedDecember31,2024,were23,177,353, up 9% from 21,263,254in2023,drivenbyincreasesinresearchanddevelopmentandgeneraladministrativeexpenses[222].−Researchanddevelopmentexpensesincreasedby902,859 (6%) to 16,806,548in2024,primarilyduetohighersalaryandbenefits,equipmentdepreciation,andprototypedevelopmentcosts[222].−Generalandadministrativeexpensesroseby1,011,240 (19%) to 6,370,805in2024,attributedtoincreasesinsalary,consultingfees,andinvestorrelationsexpenses[225].NetLoss−ThenetlossfortheyearendedDecember31,2024,was22,535,041, an increase of 1,497,009(721,038,032 in 2023, primarily due to rising operational costs [227]. Cash Flow and Financing - Net cash used in operating activities was 15,550,515fortheyearendedDecember31,2024,primarilyduetoanetlossof22,535,041 [240]. - Net cash provided by financing activities was 14,484,291fortheyearendedDecember31,2024,including12,366,965 from the resale of common stock [242]. - The company received 12,366,965inproceedsfromthe2023PurchaseAgreementwithLincolnParkduringtheyearendedDecember31,2024[231].−Thecompanyhasenteredintoa2025PurchaseAgreementwithLincolnParktosellupto30 million of common stock over a 36-month period [235]. Assets and Liabilities - As of December 31, 2024, the company's cash and cash equivalents totaled 27,667,964,withtotalassetsof37,807,983 and stockholders' equity of 33,423,905[243].−Thecompanyhadtotalliabilitiesof4,384,078 as of December 31, 2024 [243]. - The company has a cash position that allows it to finance operations through April 2026 without needing to replenish cash reserves [234]. Strategic Focus and Growth - The company commenced commercial operations in May 2023, with a material supply license agreement for Perkinamine® chromophore materials, marking a significant step in its business strategy [215]. - The company is focusing on scaling its polymer modulator devices through partnerships with silicon-based foundries, which will enhance production efficiency and capital utilization [210]. - The company aims to expand its applications beyond telecommunications to sectors such as automotive, aerospace, and defense, leveraging its proprietary polymer technology [212]. - The company plans to continue incurring substantial research and development expenses to support the commercialization of its electro-optic materials platform and enhance its product offerings [224]. - The company plans to increase spending on research and development, marketing, and workforce expansion as part of its growth strategy [238]. Future Expenditures - The company expects to incur approximately 1,727,000inexpenditurespermonthoverthenext12months[233].−Netcashusedbyinvestingactivitieswas2,697,899 for the year ended December 31, 2024, primarily for asset additions for the Colorado headquarters facility and labs [241].